TAR-200 is an intravesical gemcitabine-releasing system for BCG-unresponsive NMIBC, evaluated in the SunRISe-1 trial. The trial's focus was on TAR-200 monotherapy, with other cohorts including ...

Focal ablation for radiorecurrent localized prostate cancer shows favorable functional outcomes compared to salvage radical prostatectomy. Current studies on salvage focal ablation are limited, but ...

Two-thirds of patients with a complete response at three months avoided cystectomy at 60 months. Among cystectomy patients, only six progressed to muscle-invasive bladder cancer, indicating low ...

Belzutifan, a HIF-2α inhibitor, is approved for von Hippel-Lindau disease and advanced renal cell carcinoma, with a focus on its safety profile. The study found 28% of patients experienced grade 3 ...

BCG-exposed non-muscle invasive bladder cancer patients often relapse, highlighting the need for effective combination therapies to prevent disease progression. Current BCG combinations with immune ...

Nadofaragene firadenovec offers a 66% probability of cystectomy-free survival at 60 months for BCG-unresponsive NMIBC with CIS ± Ta/T1 disease. The phase 3 study enrolled 107 patients, with 103 ...

The NanoKnife System received FDA 510(k) clearance for prostate tissue ablation, utilizing irreversible electroporation technology to target tumors while preserving critical functions. The PRESERVE ...

BOND-003 evaluates cretostimogene for BCG-unresponsive non-muscle-invasive bladder cancer, aiming to prevent recurrence and progression, potentially avoiding radical cystectomy. The study reported a ...

Delayed diagnosis or treatment was the primary cause of malpractice lawsuits in testicular cancer cases, accounting for 87.5% of claims. No malpractice claims were associated with surveillance ...

The trial targets intermediate-risk non-muscle invasive bladder cancer, focusing on superficial stage A, primarily low-grade tumors. Cretostimogene grenadenorepvec is compared to surveillance in a ...

Combination gemcitabine-BCG therapy demonstrated high complete response rates in BCG-exposed NMIBC patients, with 94% at 6 months and 81% at 12 months. The study reported a 97% high-grade ...

TAR-200 monotherapy achieved an 83.5% complete response rate in BCG-unresponsive high-risk NMIBC patients, with a high insertion success rate of 98.8%. The treatment was well tolerated, with most ...